| P/E (FY) | — | Sales (TTM) | $217.2M |
| Earnings (TTM) | -$202.7M | ROE | −244.45% |
| Net Margin | −103.57% | ROIC | — |
| Debt / Equity | 0.78 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 100.23% |
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases in the United States and internationally. Its lead product is IMCIVREE (setmelanotide), an MC4R agonist for POMC, PCSK1, and LEPR deficiency obesity, Bardet-Biedl, Alström, Prader-Willi, and hypothalamic obesity. It is also in Phase 3 and Phase 2 trials for several obesity indications and is developing bivamelagon, an investigational oral MC4R agonist.
| Market Cap | $7.40B | Trading Days | 2208 |
| 52W High | 122.20 |
| 52W Low | 74.50 |
| % Off High | −11.59% |
| YTD | 0.93% | 1Y | 26.10% |
| 3Y | 503.58% | 5Y | 447.87% |
| Since incept. (ann.) | 15.65% |
Single Reportable 100%
| Ann. Volatility (1Y) | 45.69% | Ann. Volatility (3Y) | 56.93% |
| Sharpe (1Y) | 0.75 | Sharpe (3Y) | 1.35 |
| Max Drawdown (1Y) | −35.54% | Max Drawdown (3Y) | −35.54% |
| Beta (3Y, vs SPY) | 1.24 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LQDA | Liquidia Corp | $7.72B | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.84B | — |
| PTCT | PTC THERAPEUTICS, INC. | $6.66B | 9.7 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.28B | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.27B | 105.9 |
| PTGX | Protagonist Therapeutics, Inc | $8.80B |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
